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I was like a child, I was lying strong 
And my father lifted me up there 
Took me to a place where they checked my body 
My soul was floating in thin-air 
 
I clung to the bed and I clung to the past 
I clung to the welcome darkness 
But at the end of the night there's a green green light 
The quiet before the madness 
 
There was a girl that sang like the chime of a bell 
And she put out her arm, she touched me when I was in hell 
When I was in hell 
[…] 
Lying on my side you were half awake  
And your face was tired and crumpled 
If I had a camera I'd snap you now  
Cause there's beauty in every stumble 
 
(Belle and Sebastian – Nobody’s Empire) 
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Introduction  
 
One of the definitions of fatigue is the decrease, perceived and 
objectively measured, of the physiological capacity to perform a job, 
however fatigue is a common symptom in the community             
(with up to half of the general population reporting fatigue                 
in large surveys) [1, 2]. 
When fatigue loses some of its typical features like: transience, is no 
longer self-limiting, and its onset cannot be explained by prevailing 
circumstances, then it is possible to speak of chronic fatigue 
syndrome. 
The first to describe a disorder similar was R. Manningham in 1750 
using the word "febricula" (or even "little fever"); G.M. Beard in 1869 
coined the term "neurasthenia" to describe a syndrome characterized 
by physical fatigue and mental exhaustion, associated with difficulty 
in concentrating, impaired memory and reduction of interest [3]. 
In 1889 Charcot has succeeded to give to the symptoms of the 
“neurasthenia”, described by Beard, a pathognomonic significance. 
Typical symptoms were neuromuscular asthenia, chronic headache, 
dyspepsia with sleepiness associated to a morbid state of mind 
characterized by intellectual weakness with impaired memory and 
depressed and irritable mood. 
Studies Charcot allowed to Ballet, in 1908, to classify the 
“neurasthenia” in 4 different types: genital, traumatic, cerebrospinal 
and feminine [3]. 
Only in 90’s the term “neurasthenia” was replaced with Chronic 
Fatigue Syndrome (CFS); precisely in 1988 the Centres for Disease 
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Control and Prevention (CDD) described an illness of debilitating 
fatigue accompanied by a various combination of symptoms using the 
term Chronic Fatigue Syndrome/Myalgic Encephalomylites [4, 5] and 
thanks to Fukuda have specific criteria that allow us to perform a more 
precise diagnosis [6]. 
Since 1988 until recent years Fukuda and other researchers have 
produced several well – established case definitions for CFS which 
has summarized in table below [7]:  
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Criteria CDC 1988 CDC 1994 London 1990 Australian 1990 Oxford 1991 Canadian Conseus 2003 
Minimum duration 
(months) 
6 6 6 6 6 6 
Functional Impairment 50% decrease in activity Substantial Not specified Significant disruption of 
usual activities 
Disabling Substantial 
Symptoms and their 
requirements by 
definition 
Sore throat 
• Painful cervical or 
auxiliary lymph 
nodes 
• Muscle pain 
• Arthralgia without 
joint swelling 
or redness 
• New headaches 
• Sleep disturbance 
• Generalized fatigue 
lasting 24 
hours or more following 
exercise 
that in a patients 
premobid state 
would have been easily 
tolerated 
• Mild fever 
• Generalized muscle 
waelness 
• Main symptom 
complex must 
have developed over a 
few 
hours/ days 
 
Requires four 
• Sore throat 
• Tender lymph 
nodes 
• Muscle pain 
• Arthralgia without 
joint swelling or 
redness 
• New headaches 
• Unrefreshing sleep 
• Post-exertional 
malaise lasting 
more than 24 
hours 
 
The following three 
symptoms must be 
present 
• Symptom 
fluctuation brought 
about and 
precipitated by 
physical or mental 
exercise 
• Exercise-induced 
fatigue 
• Impairment of 
short-term 
memory and loss 
of powers of 
concentration 
 
The following two 
symptoms must be 
present 
• Chronic persisting/ 
relapsing fatigue 
• Fatigue is 
exacerbated by 
minor exercise 
None required 
symptoms of muscle 
pain, mood and 
sleep disturbance 
 
The following three 
symptoms 
must be present 
• Significant muscle 
pain 
• Post-exertional 
malaise and/or 
fatigue lasting 24 hours 
or more 
• Sleep dysfunction 
A further one symptom 
from two 
of the following 
categories of 
• Immune 
• Neuroendocrine 
• Autonomic symptoms 
is required 
 
Cognitive and 
Neuropsychiatric 
Symptoms 
Requires one or more 
of symptoms 
 
Requires 
• Impairment of 
short-term 
Requires 
• Short-term 
memory 
Requires 
• Neuropsychiatric 
dysfunction which 
Requires 
• Mental fatigue 
 
Requires two or more 
symptoms 
of 
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• Forgetfulness 
• Irritability 
• Confusion 
•Concentration 
difficulties 
• Depression 
• Photophobia 
• Difficulty thinking 
 
memory 
• Concentration 
difficulties 
 
difficulties 
• Concentration 
difficulties 
• Emotional liability 
• Nominal dysphasia 
 
includes new 
onset memory 
impairment 
 
• Confusion 
• Short-term memory 
problems 
• Concentration 
difficulties 
• Disorientation 
• Information 
processing problems 
• Word retrieval 
problems 
• Perceptual and 
sensory 
disturbances 
• Ataxia 
• Photophobia 
• Hypersensitivity to 
noise/emotion 
 
New Onset  Required Required Not Required Not Required Required Required 
Medical Exclusion Extensive list of known 
medical causes 
Clinically Important Extensive list of known 
medical causes 
Known physical causes Known physical causes Extensive list of known 
medical causes 
Psychiatric Exclusion Bipolar disorder 
• Substance abuse 
• Schizophrenia 
• Anxiety disorder 
• Depressive disorder 
 
Bipolar disorder 
• Substance abuse 
• Eating disorder 
• Schizophrenia 
• Severe melancholic or 
Psychotic depression 
• Dementia 
• Delusional disorder 
• Primary depressive 
illness 
• Anxiety neurosis 
 
• Bipolar disorder 
• Substance abuse 
• Eating disorder 
• Psychosis 
 
Bipolar disorder 
• Substance abuse 
• Eating disorder 
• Psychosis 
 
• Primary psychiatric 
disorders 
• Substance abuse 
 
Table 1: Variability of case definition criteria for CFS [7]  
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The most prominent similarity between the definitions shown in the 
table was the necessity for symptoms to be present for 6 months or 
more. Almost all included a requirement for fatigue to be present, with 
the exception of the 2003 Canadian definition [8] which focused not 
on fatigue but on post-exertional malaise [7]. 
CFS, like many chronic illnesses, is proving difficult to define and 
despite more than 30 years of research, continues to be a poorly 
understood and controversial syndrome [9]. 
Between all the case definitions views, to date, with exception, that of 
Fukuda of 1994, is the most the most frequently used and has created 
a unified approach to the definition and study of CFS [7, 10]. 
 
DEFINITION CRITERIA 
 
Clarification of the relation between the chronic fatigue syndrome and 
the neuropsychiatric syndromes is particularly important.[6] 
In order to guide the development of studies relevant to the CFS, 
Fukuda proposed a framework the clarified the need to compare 
population defined by chronic fatigue syndrome with several other 
populations in case – control and cohort studies.[6] 
Figure 1 show a conceptual framework of abnormally fatigued 
populations, including those with the CFS and overlapping disorders. 
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Figure 1: A conceptual framework of abnormally fatigued populations, including those with the 
chronic fatigue syndrome (CFS) and overlapping disorders [6] 
Thanks to Fukuda studies now we have an evaluation and 
classification of unexplained chronic fatigue (figure 2)  
 
Figure 2: Evaluation and classification of unexplained chronic fatigue; ALT: alanine 
aminotransferase; BUN: blood urea nitrogen; CBC: complete blood count; ESR:: erytrocite 
sedimentation rate; PO4: phosohorus; TS: thyroid stimulating hormone; UA: urinalysis [6] 
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Summarizing the data in the chart above a case of CFS is defined by 
the presence of the following:  
1. Clinically evaluated, unexplained, persistent on relapsing 
chronic fatigue that is of new ore definite (as note been 
lifelong); in not the result of ongoing exertion: is not 
substantially alleviated by rest; and results in substantial 
reduction in previous levels of occupational, educational, social 
or personal activities. 
2. The concurrent occurrence of four or more of symptoms (like 
sore throat, tender cervical, muscle pain, headaches) all of 
which must have persisted or recurred during 6 or more 
consecutive months of illness and must not have predated the 
fatigue[6].  
 
 
Panel 1: 1994 case deﬁnition for CFS from US Centers for Disease Control and Prevention [11] 
Another interesting algorithm that allows us to make a diagnosis of 
CFS is given by Barbado [12]. 
We can observe by this scheme that the conditions that exclude 
diagnosis of CFS are: psychiatric disorders, such as a major 
Characterised by persistent or relapsing unexplained chronic fatigue 
 Fatigue lasts for at least 6 months 
 Fatigue is of new or deﬁnite onset 
 Fatigue is not the result of an organic disease or of continuing exertion 
 Fatigue is not alleviated by rest 
 Fatigue results in a substantial reduction in previous occupational, 
educational, social, and personal activities 
 Four or more of the following symptoms, concurrently present for ≥6 
months: impaired memory or concentration, sore throat, tender cervical or 
axillary lymphnodes, muscle pain, pain in several joints, new headaches, 
unrefreshing sleep, or malaise after exertion 
Exclusion criteria 
 Medical condition explaining fatigue 
 Major depressive disorder (psychotic features) or bipolar disorder 
 Schizophrenia, dementia, or delusional disorder 
 Anorexia nervosa, bullaemia nervosa 
 Alcohol or substance abuse 
 Severe obesity 
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depression, schizophrenia eating disorders (anorexia bulimia) bipolar 
disorders, alcohol or other substances abuse, in addition to morbid 
obesity, and active medical diseases, either non treated or without a 
completely established resolution [13]. 
 
Figure 3: diagnostic protocol for patients with suspected CFS [13] 
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Core symptoms found by Fukuda were included in 2003 in the 
Canadian Consensus Criteria [4, 14] 
Its application in research however, suggests that patients fulfilling the 
Canadian definition have more severe impairment to their physical 
functioning and cognition than 1994 CDC defined patients [15, 16]. 
The Canadian definition was revised in 2011 and renamed the 
International Consensus Criteria (ICC) [17] 
A major criticism of the 1994 CDC definition is that it has remained 
the most common criteria for CFS/ME due to consensus [18]. 
The ICC was proposed based on collective empirical findings on 
dysfunction found in CFS/ME patients fulfilling broader definitions of 
the illness [19-29]. 
These findings, however, may be more prominent in a more 
homogenous sample. The potential of the ICC to identify a distinct 
subgroup of CFS/ME may, therefore, enhance the opportunity of 
discovering a unique biological marker for the illness [4]. 
 
EPIDEMIOLOGY  
 
The difficulties with definitions have affected the results of 
epidemiological studies and in this way prevalence varies widely [11] 
and it is known that knowing the prevalence of a disease allows us to 
understand its impact on public health, to plan resources based on its 
expected prevalence and program based on its temporal variation. 
Estimates of the prevalence of CFS have varied depending on which 
definition was used, the type of population that was surveyed, and the 
study methods [30]. 
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Unfortunately few reliable and valid epidemiological data on CFS are 
available [11]. People of every age, gender, ethnicity and 
socioeconomic group can have CFS but it affects women at six times 
the rate of men [31]. 
The estimated prevalence of CFS is much lower among children and 
adolescents than among adults [32-34]. 
Some demographic data show that in most studies 75%                       
or more of patients with CFS are female; early reports from         
tertiary clinics suggested that CFS affected primarily young,       
white, successful women. The mean age at onset of CFS                     
is between 29 years and 35 years. The mean illness duration ranges 
from 3 years to 9 years [3, 35-37]. 
In the Chicago community-based sample, gender predicted fatigue 
severity, with women exhibiting higher fatigue scores than men. Also, 
within this sample women had significantly poorer physical 
functioning, more bodily pain, poorer emotional functioning, 
significantly more severe muscle pain, and significantly greater 
impairment of work activities [38, 39]. More than 80% of CFS 
sufferers go undiagnosed [40].  
However, community surveys have found that white individuals have 
a lower risk of CFS, compared with Latinos [36], African Americans . 
[37, 41], and Native Americans [36]; nevertheless, ethnic minority 
status does not always confer a risk and although CFS show an 
association with ethnicity, fatigue does not.  
Nevertheless this result needs to be replicated in future research as 
there were only two studies for CF and only one study for CFS that 
compared Native American and African American with White people 
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and all three studies found a higher prevalence of CF and CFS in 
ethnic minority groups [42]. 
These disparate findings suggest that the increased prevalence of this 
syndrome among whites in clinic populations is most likely the result 
of a bias attributable to health care access and utilization [3].  
 
 
 
AETIOLOGY  
 
Many studies have investigated the aetiology and pathogenesis of 
CFS; most of those carried out between 1980 and 1995 concentrated 
on the physical aetiology of CFS, with a slight shift towards 
psychological and psychiatric research in the next few years [43]. 
Despite all of these studies, however, the real aetiology of chronic 
fatigue syndrome remains elusive [3]. 
As the criteria for CFS diagnosis are not based on the understanding 
of aetiopathogenic mechanisms, some patients present similar clinical 
manifestations but are diagnosed with other conditions because fatigue 
is not the primary symptom. Some of those conditions are 
fibromyalgia, irritable bowel syndrome, and temporomandibular joint 
syndrome. Furthermore, in addition to sharing several symptoms with 
CFS, currently available evidence suggests that those diseases also 
share similar pathophysiologic mechanisms [44, 45]. 
Although the aetiology and the pathogenic mechanisms of CFS are not 
fully understood, several hypotheses have been postulated, being the 
disorders of the central nervous system neuromodulator the one 
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supported by more evidence to explain the possible pathogenic 
mechanisms involved in CFS [46]. 
Many somatic and psychosocial hypotheses on the aetiology of CFS 
have been explored. Explanations for CFS were sought in viral 
infections, immune dysfunction, neuroendocrine responses, 
dysfunction of the central nervous system, muscle structure, exercise 
capacity, sleep patterns, genetic constitution, personality, and 
(neuro)psychological processes [11].  
Although several studies found abnormalities, only a few                
were diagnosed in large groups of patients with CFS                         
and were independently confirmed in well-controlled studies,            
an exception being the subtle changes in                                            
the hypothalamopituitary-adrenal axis [47].  
The aetiology and pathogenesis are generally believed to be 
multifactorial [48]. 
Distinction between categories of predisposing, precipitating,          
and perpetuating factors is useful for understanding of this complex 
disorder. The assumption is that one or more factors of each               
of these categories is conditional but insufficient                               
for development of CFS [49-53]. 
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Predisposing Factors 
 
Some studies have shown that personality and lifestyle can affect the 
vulnerability of the subjects to the CFS; neuroses and introversion 
have been reported as risk factors for the disorder [54].  
In adults, the risk of CFS increases if high inactivity in childhood or 
after mononucleosis [53, 55].  
Also genetics may play a role predisposing, since women are        
more prone to CFS than men at the same time, however, studies         
of twins have shown a predisposition familiar but no                  
genetic abnormality [56-58]. 
 
Precipitating Factors 
 
The onset of CFS can be due to several factors: acute physical or 
psychological stress [59]; for three-quarters of patients the trigger of 
the disease was identified in infection, like a, flu-like illness cold, or 
infectious mononucleosis [59, 60]. A causal relationship was also 
found with infectious mononucleosis [49, 61-63] and finally found 
high rates of chronic fatigue after Q fever and Lyme disease [63].  
However, differences were found in the load of Epstein-Barr virus and 
immunological reactivity among individuals who developed CFS and 
those that have not done so [64, 65]. 
Precipitating somatic events, such as serious injury, surgery, 
pregnancy, or labor, which are reported as the onset of CFS by 
patients, have not been studied systematically. Psychological stress as 
a trigger of CFS has also been studied.                                                
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Severe life events, such as the loss of a loved one or a job, and other 
stressful situations were found to precipitate the disorder [66, 67]. 
 
Perpetuating Factors 
 
Once CFS has developed, several maintaining factors can impede 
recovery. Psychological processes seem to be involved in the 
perpetuation of complaints in patients with CFS. These processes 
involve ideas or cognitions of patients about complaints and 
behavioural factors such as persistent avoidance of activities 
associated with an increase in symptoms [11]. A strong belief in a 
physical cause of the illness, a strong focus on bodily sensations, and a 
poor sense of control over complaints contribute to an increase in 
fatigue severity and functional impairment [68-71].  
Other perpetuating CFS factors that have been identiﬁed are social 
processes ranging from solicitous behaviour [72] to lack of social 
support [73].  
Illness perceptions and illness behaviour can be reinforced by people 
in the patient’s environment, such as a partner or family [74-76]. 
Practitioners can contribute to the persistence of CFS by continuously 
encouraging unnecessary medical diagnostic procedures, by 
persistently suggesting psychological causes, or by not acknowledging 
CFS as a diagnosis, thus causing communication problems [77, 78]. 
Apart from the many disadvantages, long-lasting illness can also have 
more desirable consequences, such as care, attention, disengagement, 
or even ﬁnancial beneﬁts, which might also be considered 
perpetuating factors [72, 79]. 
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NEUROENDOCRINOLOGICAL THEORY 
 
In patients with fibromyalgia, the research on neurotransmitter 
disorders has started to yield positive findings, and it is known that 
different clinical manifestations will appear according the type and the 
site of action of affected neurotransmitters [44, 80] 
Other studies reported that abnormalities in the hypothalamic-
pituitary-adrnal (HPA) axis and serotonin pathways gave been 
identified in CFS patients, suggesting an altered physiological 
response to stress [81, 82]. 
CFS seems to also affect the production of some neurotransmitters: 
About one-third of patients have been shown to exhibit 
hypocortisolism, which appears to originate from a CNS source rather 
than a primary adrenal site [83]. 
In addition, studies have demonstrated abnormalities of CNS 
serotonin physiology in patients with chronic fatigue syndrome [81]. 
The studies of abnormalities in HPA function, hormonal stress 
responses, and serotonin neurotransmission in CFS patients have 
generated the most reproducible and robust findings reported to            
date [3]. 
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ROS THEORY 
 
Several groups of investigators assume that a defective oxidative 
phosphorylation and subsequent free radical production and   
oxidative stress play an important role in the pathophysiology of 
CFS/ME [27, 28, 84-91].  
Moreover, the level of oxidative stress correlates with the severity of 
symptoms [91]. 
One research found increased levels of MDA (malondialdehyde, a 
potential biomarker of oxidative damage and disease severity) and CO 
levels in the CFS group and that the oxidative stress was present in 
their group of female patient [92]. Another one shown that CFS 
patients have a lipid profile and oxidant biology that is consistent with 
cardiovascular risk [93] 
 
INFECTUS THEORY 
 
As for this theory literature expresses different opinions; on one hand, 
in fact, Epstein-Barr virus, human herpesvirus 6, group B coxsackie 
virus, human T-cell lymphotrophic virus II, hepatitis C, enteroviruses, 
and retroviruses have been proposed as etiological agents in chronic 
fatigue syndrome. Research is focusing on a potential marker for viral 
infection [94]. On the other side, there has been no consistent 
evidence to date that chronic fatigue syndrome results from a specific 
infection [3]. According to Engleberg the pathogenic relationship 
between infection and the CFS has not been demonstrated [95]. 
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There is also disagreement about the function of some vaccines; 
vaccines have been depicted by some researchers as playing an 
important role in CFS onset [96, 97], while on the other hand, others 
scholars have rejected this possibility, affirming that the vaccine is 
safe [98, 99]. 
 
GENETIC AND TWIN STUDIES 
 
We have seen how difficult it is to prove the exact aetiology of this 
syndrome; to understand the relative importance of genetic and 
environmental influences on the development of this disorder, 
investigators researchers have tried to demonstrate its heritability and 
its familiarity with different types of studies (family,                         
adoption, or twin studies).  
Several other investigations have suggested that a combination of host 
and environmental factors may be involved in the etiology                 
of CFS [58]. 
However, up to now have been few studies of this type (we just know 
that it was not carried out any study of adoption) [3]. 
In the family history study the results, based on subjects’reports of 
illness in family members, suggested that within relatives of patients 
with chronic fatigue syndrome there were significantly higher rates of 
the same syndrome than in relatives of comparison subjects [100]. 
Twin studies have been useful in elucidating the relative contributions 
of genetic and environmental factors to numerous medical and 
psychiatric disorders, and they are especially helpful for the study of 
diseases of unknown cause  and have been widely used to estimate the 
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heritability of numerous complex disorders and conditions [58, 101].  
Investigators have used twin methodology to determine how much of 
the family aggregation described is due to genetic factors and how 
much to the environment. Twin studies in adults have shown 
consistently higher concordance rates in monozygotic twins compared 
to dizygotic twins for CFS/ME, with the monozygotic correlation 
usually at least twice that of the dizygotic correlation [58, 102-105]. 
Despite different populations, highly variable case definitions of 
fatigue and few data available, these type of study found evidence to 
support a familial effect [58]. 
In summary, there is now increasingly strong evidence that CFS/ME 
is heritable. It seems likely that the heritability contributes to the 
experience of fatigue as well as to the development of CFS/ME itself.  
Although there is some agreement that a model involving the joint 
action of genes and environment is required, there is currently little 
agreement on the actual genes and environmental factors involved 
[102].  
An important observation reported by Buchwald in his study is that 
heritability increased our definition of chronic fatigue has been made 
more stringent. This suggests that future research would benefit from 
distinguishing CFS from milder forms of chronic fatigue [58]. 
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COMMORBIDITY 
 
The difficulty during these years of research to find a      
physiological, stable and consistent marker for this syndrome has 
pushed some scientist to say that CFS is primarily a                                   
psychiatric disorder [3, 106, 107]. 
In several research Chronic Fatigue Syndrome is described in relation 
to psychological stress as a work that causes abnormal nictemerale 
rhythm, or works that cause restrictions. The presence of a physical 
and / or psychological stress seems to be of great importance as a 
causative factor in the pathogenesis of CFS cases [3, 108]. 
Other studies reported that persons with CFS experienced signiﬁcantly 
more stressful life events in the year before illness onset than controls 
during the same calendar time-period [109-112]. 
Several stress research has repeatedly shown that the qualitative 
evaluation of a life event as negative is crucial in its subsequent effect 
on health and no studies of which we are aware have measured stress 
perception, occurrence of stressful life events and stress levels within 
the same study [112]. 
Investigation conducted by Nater compared subjects with CFS with 
healthy subjects and showed that exposure to stressors was 
signiﬁcantly more common in persons with CFS compared to the 
healthy controls; those with CFS reported experiencing        
signiﬁcantly higher levels of psychological distress; and, post-
traumatic stress disorder (PTSD) was more                                    
common in people with CFS [112]. 
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Another study found that a lifetime diagnosis of CFS was strongly 
associated with both lifetime PTSD and current traumatic symptoms, 
as measured by the IES (impact of events scale), in a large 
community-based twin registry. A role in the association between CFS 
and PTSD can be play by the stress-response system in general, and 
the hypothalamic-pituitary-adrenal (HPA) axis in particular [113]. 
Dansie et al. demonstrated that both animal and human studies have 
shown that traumatic early life stressors may permanently change    
the stress response system in ways that leave affected           
individuals more prone to the effects of other stressors and to      
stress-related disorders [113-116]. 
Results obtained by Dansie are very interesting and have substantial 
relevance to practitioners and researchers alike because support 
previous results on the comorbidity of CFS with PTSD, and they 
extend the literature to include the potential role of familial and 
unique environmental factors in the link between these two conditions. 
Dansie argue that clinicians should carefully and thoroughly    
consider the complex nature of CFS as it relates to other conditions, 
and follow a multifaceted treatment approach that addresses             
the potential common mechanisms, such as the hormonal         
changes previously discussed, which underlie both CFS                   
and stress-related conditions. [113]. 
Panic disorder and generalized anxiety disorder are also common 
comorbid conditions among those with chronic fatigue syndrome, 
although the syndrome is differently characterized across studies. 
Some articles points to an overlap between CFS and anxiety.          
The simple comorbidity of chronic fatigue syndrome and anxiety 
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disorders, however, does not suggest that chronic fatigue syndrome is 
a physical manifestation of an anxiety disorder [3]. 
A study carried out by Chan and his colleagues. on effects of Qigong 
Exercise on patients affected by CFS demonstrated that the 
participants’ anxiety symptoms were significantly improved in both 
groups compared with baseline values [117]. 
Despite several limitations, this study also showed a significant 
correlation between alleviation of depression and fatigue reduction,   
as well as reduced anxiety following Qigong exercise; furthermore 
Qigong exercise may be effective in reducing fatigue symptoms       
and alleviating depressive symptoms for patients with CFS-like illness 
and that the improvement of fatigue symptoms may predict              
the alleviation of depressive symptoms after Qigong intervention.    
The most interesting part of this work concerns the association 
between fatigue symptoms and psychiatric disorder, association 
confirmed by results [117-120]  
Another example of commorbidy concerns sleep disorders.  
Indeed, CFS patients report more difficulty falling asleep, more 
interrupted sleep, and more daytime napping than healthy or 
chronically ill comparison subjects[3, 121]. However, it is unclear 
whether they also experience excessive daytime sleepiness (EDS) [3].    
To date this correlation is very unclear: the semiological distinction of 
fatigue and sleepiness is diﬃcult both for patients and clinicians, 
leading to possibly imprecise diagnostic formulations [122].  
Moreover the relationships of sleepiness or fatigue to sleep remain 
insufficiently understood [122, 123]. 
Complaints of fatigue and sleepiness can overlap in patients,            
but should be taken into account separately as they may              
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express very different etiologies and may imply different treatment 
considerations [124]. 
Persons with chronic fatigue syndrome have high rates of current and 
lifetime major depression, which has been taken as evidence that 
chronic fatigue  syndrome is an atypical manifestation of             
major depression. On the other hand, the high rates of depression        
in this syndrome could be a result of overlapping symptoms,                
(emotional response to disabling fatigue, viral or immune changes, 
alterations in brain physiology).In fact, several lines of               
research have suggested that CFS and major depression are possibly 
distinct entities [3] 
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TREATMENT AND RECOVERY 
 
We have seen in previous sections that CFS is a chronic process that 
becomes a social disease due to the incapacity that it causes in the 
person who suffers to continue to fulfill their work, social and family 
responsibilities. The specific characteristics of the symptomatology of 
patients with CFS require a rapid adaptation of the educational, 
healthcare and social systems to prevent the problems derived from 
current systems.  
At present, no curative treatment exists for patients with CFS. 
Treatment objectives must be focused on improving the clinical 
manifestations, maintaining the functional capacity and quality of life, 
and developing a tailored programme, providing each patient with the 
maximum perception of improvement. Patients with CFS require 
multidisciplinary management due to the multiple and different issues 
affecting them. This multidisciplinary management requires 
coordination between the different specialists, which leads to the need 
for the existence of an Action Protocol to establish the intervention 
procedure according to the needs of each patient. As mentioned above, 
CFS is disabling in some patients [13] 
CSF remains a difficult disease to be treated effectively [125]; 
according Arroll individualised treatment protocols which include a 
range of tailored strategies are a favourable direction for dealing with 
a complex and multisystem disorder such as ME/CFS [126].  
The subtle changes found in the hypothalamopituitary-adrenal axis 
have led to two randomised controlled trials, on the basis of which the 
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researchers have not concluded that steroids are the treatment of 
choice [127, 128]. For immunological interventions such as 
immunoglobulin, the evidence has been inconclusive. There has also 
been insufﬁcient evidence of the effectiveness of pharmacological, 
supplementary, complementary, and other interventions [129]. 
According to some studies, cognitive behaviour therapy (CBT) and 
graded exercise therapy (GET) are the only interventions found to be 
beneﬁcial. This therapy is a general form of psychotherapy directed at 
changing condition-related cognitions and behaviours. Central CBT 
components for CFS include explanation of the aetiological model, 
motivation for CBT, challenging and changing of fatigue-related 
cognitions, achievement and maintenance of a basic amount of 
physical activity, gradual increase in physical activity, and planning 
work rehabilitation or rehabilitation in other personal activities. CBT 
teaches patients with CFS how to acquire control over symptoms. 
CBT for CFS is based on a behavioural model of avoidance and 
always includes a graded activity programme. GET is based on a 
physiological model of deconditioning and has no intention of 
explicitly treating cognitions [11].  
In adolescents, cognitive behaviour therapy combined with other 
group therapies that promote treatment compliance and sharing 
experiences or thoughts with other adolescents is very useful, even 
when they do not have identical pathologies. It must be noted that 
there is very limited evidence on cognitive therapy in adolescents. 
Some non-controlled studies suggest that this therapy reduces fatigue 
in young people [130, 131] with early intervention [13]. 
However, not all patients beneﬁt from CBT or GET [11].  
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Results obtained by Tirelli, instead showed that a significant number 
of patients treated with antiviral/immunoglobulin approaches have a 
long positive disease free survival in comparison with other patients 
treated with the other approaches (i.e., antidepressants, corticosteroids, 
and supplements) [125]. 
Some studies in the past have tried to show if complementary and 
alternative medicine (CAM) were effective against chronic fatigue; 
however, was never reached a sufficient number of tests to determine 
their effectiveness in a definitive way [132]. 
A recent systematic review of the prognosis of CFS showed that full 
recovery without treatment is rare. [35]. 
Most prognostic studies were done in specialist centres with a        
bias towards severe cases. The duration of follow-up of        
prognostic studies ranged from 1 year to 5 years.                              
The median recovery rate was 5% (range 0–31%) and the median 
improvement rate 39·5% (range 8–63) [11]. 
The relatively small proportion of recovered patients may reﬂect the 
heterogeneity of CFS [133]. 
One last alternative therapy was provided to us by Chan; his results on 
the Qigong  suggest that the exercise of this ancient self-healing is an 
ancient mind-body exercise can be used as an alternative and 
complementary therapy or rehabilitation program for patients with 
CFS-like illness [117]. 
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PROTEOMIC STUDIES 
 
We have seen how difficult it is to define aetiology of chronic fatigue 
syndrome; for this reason, in recent years, several studies have been 
conducted proteomic type that would allow the identification of 
biomarkers useful for research and therapy. 
A study of Schutzer et al. that has compared CFS and Neurologi Post 
Treatment Lyme disease Syndrome (nPTLS), in addition to 
demonstrating that the two syndrome there is no correlation between 
the proteomes despite similar symptoms, showed that CFS proteome 
analysis can provide important and meaningful insights into biological 
processes modulated as a function of the disease and facilitate the 
identification of protein candidates for further investigation [134]. 
Another study instead demonstrated that the CFS, PGI and FM 
subjects had a significant overlap between their syndromes. Despite 
the differences in their original case designations, they had very 
similar responses on questionnaire, quality of life and nociceptive 
measures. Again, despite the differences in the diagnostic label 
applied to them for study entry, their cerebrospinal fluid proteome 
demonstrated reproducible constituents [135].  
Instead, the study of Ciregia correlates proteomic and twin studies. 
This research started from a previous study on monozygotic twins 
discordant for CFS, that did not identify a biomarker for CFS in the 
transcriptome of peripheral blood leukocytes, and moved to the study 
of proteins, using a proteomic approach to investigate the proteomics 
salivary profile in a couple of monozygotic discordant for CFS [136, 
137].  
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Aim of Work  
 
Our study moves from the previous research conducted by Ciregia 
which, however, was limited to only a couple of monozygotic twins 
discordant for CFS. The study of 2013 pointed out some proteins 
which are useful both to define a panel of potential diagnostic 
biomarkers and to shed new light on the comprehension of the 
pathogenetic pathways of CFS [136].  
Our research was born, then, from the need to extend the results 
obtained from the twin study on a larger number of subjects with 
similar medical history and continue the search for biomarkers useful 
for both diagnosis and therapy of this syndrome. 
Using different techniques (2-DE; western blot and ELISA – kit ), 
with a proteomic approach, we tried to confirm the biomarkers found 
in past studies and to seek new ones.  
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Methods  
 
SUBJECTS 
 
A consecutive sample of 41 subjects with a diagnosis of CFS was 
recruited at the Rheumatology outpatient Unit of the University of 
Pisa between June 2010 and January 2011, The diagnosis of CFS and 
FM was made according to the ACR criteria by a rheumatologist. 
Subjects included new and continuing patients, of at least 18 years of 
age, according to the classification criteria of Fukuda of 1994.        
The Ethics Committee of the Azienda Ospedaliero-Universitaria 
Pisana approved all recruitment and assessment procedures.             
All patients interested in take part in the study underwent a psychiatric 
assessment after a routinely appointment. Eligible subjects provided 
written informed consent after receiving a complete description of the 
study and having an opportunity to ask questions. 
Medical history of each patients was carefully recorded focusing in 
particular on comorbidities and concomitant medications.         
Moreover, as far as serological data is concerned, complete blood 
tests, non organ specific auto-antibodies (Antinuclear antibodies, 
ENA, Ra-test and ACLA) and thyroid hormones and thyroid specific 
autoantibodies were detected in all the cases. Hepatitis B and hepatitis 
C infections were excluded as well in all the participants.          
Finally, every patient had a psychiatric specialist evaluation to assess 
psychiatric concomitant disorders. The TP count was determined by 
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the number of TPs that had a threshold of 4 kg/cm². Each positive TP 
had a pain score between 0 and 10. Psychiatric diagnoses were made 
through the Structured Clinical Interview for the DSM-IV Axis I 
disorders (SCID-I/P) (129), administered by psychiatrists trained and 
certified in its use at the “Dipartimento di Psichiatria, Neurobiologia, 
Farmacologia e Biotecnologie” of the University of Pisa, Italy.  
The following questionnaires were also administered:                       
the MOODS-SR lifetime version [138], the PAS-SR lifetime version 
[139], the Software CNS Vital Signs, tests for the assessment of 
neurocognitive tasks [140] and the Fibromyalgia Impact 
Questionnaire (FIQ) [141]. 
The FIQ (Fibromyalgia Impact Questionnaire) [141-144], is a 
questionnaire of 10 questions that assess the physical, occupational, 
depression, anxiety, sleep, pain, stiffness, fatigue and well-being in 
patients with FM. The higher scores indicate a worse quality of life. 
The HAQ ("Health Assessment Questionnaire") [145, 146] is used for 
patients with various rheumatic diseases: disability is assessed by 8 
categories of questions designed to verify if the patient has difficulty 
in dressing, arising, eating, walking, bathing, reaching objects, 
shaking objects and doing activities. 
The FACIT-Fatigue Scale questionnaire (Functional Assessment of 
Chronic Illness Therapy-Fatigue Scale) [147] is a collection of 
questions related to the quality of life aimed at chronic disease 
management. It consists of 13 questions that investigate the fatigue, 
the ability to perform everyday skills, the need for sleep, the need of 
help to perform daily activities, and how physical state affects the 
psychic state. 
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Socio-demographic data were collected using interviewer-
administered questionnaires. A structured interview format was used 
to record sex, age, educational level, marital status, employment and 
duration of illness (table 2).  
Were enrolled in the study 41 healthy subjects with similar mean age 
and demographic characteristics. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Questionnaire score and scales of CFS patient: mean of various parameters of 41 
subjects affected by CFS  
FACIT 30,38 
FIQ 54,61 
VAS pain 3,51 
VAS fatigue 7,67 
VAS sleep 7,35 
HAQ 0,41 
SF 36  
Physical functioning 60,28 
Role Physical 16,67 
Bodily Pain 47,72 
General health status 35,67 
Vitality 25,83 
Social activities 33,17 
Mental health 60,22 
Role Emotional 42,33 
37 
 
WHOLE SALIVA SAMPLES: COLLECTION AND 
PREPARATION 
 
We decided to use whole saliva (WS) because recently, the number of 
publications related to salivary proteome have significantly increased 
suggesting human saliva as a biological fluid with an enormous 
potential to reflect systemic health conditions. Saliva has many 
advantages in terms of low invasiveness, minimum cost, and easy 
sample collection and processing. Moreover, saliva has a less complex 
protein composition than serum or plasma reducing the risk of non 
specific interactions, and at the same time it represents a useful 
diagnostic tool since about 30% of blood proteins are also present in 
saliva [136, 148].  
Unstimulated whole saliva samples were collected early in the 
morning (between 8 and 10 a.m.) in standard conditions, i.e. all the 
subjects were asked to be on an empty stomach, without having 
assumed any drinks or any kind of food (including gum or candies) 
since the night before. In order to minimize the degradation of the 
proteins, the samples were processed immediately and kept on ice 
during the process. Between 1-3 ml saliva was obtained from each 
subject. To remove the debris and the cells, a centrifugation at 14000 
g for 30 min at 4 °C, was performed and the protein amount of 
resulting supernatants was estimated using a DC protein assay from 
Bio-Rad. Bovine serum albumin (BSA) was used as a standard.        
All subjects (CFS and healthy) were randomly pooled in order to 
obtain 6 pools for each class; 200 µg for each pool were          
solubilised with rehydration solution  
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(Urea 7M – Tiourea 2M, Chaps 4%, Ditiotreitolo -DTT- 60mM, Blu 
di Bromofenolo 0,002%) filled up to 400µl and supplemented with 
1.2% IPG Buffer pH3-10.  
Each experiment were performed in duplicate.  
 
2-DE ANALYSIS 
 
Isoelectrofocusing (IEF) was carried out by using 18cm Immobiline 
Dry-Strips (GE-Healthcare) with a linear pH 3-10, gradient.                  
IEF was performed at 16°C on a Ettan IPGphor II                   
apparatus (GE Health Care) according to the following schedule: the 
strips were swollen for 24h onto Reswelling tray IPG, then they were 
moved on manifold and the voltage was linearly increased from 200 V 
to 5000 V during the first 4 h, and then stabilized at 8000 V for 10 h. 
Before the second dimension, IPG strips were equilibrated for 15 min 
in 50 mM TrisHCl, pH 8.8, 6 M Urea, 30% glycerol, 2% SDS, 
0.002% bromophenol blue, 1% DTT, and subsequently for 10 min in 
the same buffer solution but substituting the 1% DTT with 2.5% IAA.             
The equilibrated strips were applied to the top of 12.5% SDS-PAGE 
gels (21cmx20cmx1.5mm) and electrophoresis was performed using 
the PROTEAN Plus-Dodeca Cell (Bio-Rad) with constant amperage 
at 192mA and 15 °C for 14h (over-night) applying a continuous buffer 
system. 
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Staining and image analysis 
 
Gels were stained with ruthenium II tris (bathophenanthroline 
disulfonate) tetrasodium salt (Sunatech Inc.) essentially as described 
by Rabilloud et al. [99]. Briefly, after electrophoresis, gels were fixed 
in 1% phosphoric acid (v/v) and 30% ethanol for 1h at room 
temperature, then were stained overnight with 1mM ruthenium 
complex (RuPB) in 1% phosphoric acid (v/v) and 30% ethanol.         
The day after the gels were destained for 4-6 hours in 1% phosphoric 
acid and 30% ethanol and rinsed in water prior to acquisition on 
fluorescence by “ImageQuant LAS4010” (GE-Healthcare).              
The images were analyzed with the Progenesis SameSpot (Non linear 
- Dynamics) software program. 
 
Statistical analysis 
 
Anova test has been used to explore qualitative and quantitative 
differences in the protein expression between CFS and health patients. 
We selected only proteins whose expression showed over 2-fold spot 
quantity change in FM samples. The significance of the differences 
was expressed by p-value <0.05.  
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WESTERN BLOT 
 
Proteins of interest detected by MS/MS were also identified by 
Western Blotting (WB). WS samples were mixed with SDS sample 
buffer (Laemmli solution) and heated at 100°C for 5 min. Amounts of 
the samples, corresponding to 50 μg of proteins for transaldolase and 
2,5 μg for PGAM1, were run on 12 % SDS-PAGE gels and 
transferred onto nitrocellulose membranes (0.2 μm) using a voltage of 
100 V for 30 min (Criterion Blotter, Biorad). Non-specific binding 
was prevented by blocking the membranes with 3% low fat dried 
milk, 0.2% (v/v) Tween 20 in PBS (10 mM NaH2PO4, pH 7.4, 0.9% 
NaCl) (PBS/milk) overnight at 4°C. After blocking, the membranes 
were incubated for 2 h at RT in PBS/milk containing primary antibody 
After 4 washes with PBS/milk, we incubated the membranes with 
peroxidase-labeled secondary antibody. Proteins were revealed with 
an enhanced chemiluminescence detection method according to the 
manufacturer’s instructions (PerkinElmer). 
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ELISA KIT  
 
The concentration of proteins was also determined using commercial 
ELISA kit (USCN Life Science Inc., Wuhan, China) according to the 
manufacturer’s instruction.  
Amounts of 100ul of sample, whole or diluted saliva, were assayed; 
for the dilution of WS samples we used a phosphate buffer saline PBS 
20mM pH 7.15.  
Absorbance values were measured spectrophotometrically  at a 
wavelength of 450nm by Wallac Victor 2, 1420 label (Perkin Elmer). 
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Results and Discussion 
PROTEOMIC ANALYSIS OF HEALTHY AND CFS 
WHOLE SALIVA SAMPLES 
A comparative proteomic analysis was performed on CFS and healthy 
samples using 2D followed by nanoLC-ESI-MS/MS. Typical 2D gel 
image of salivary proteins profiles is shown in Fig. 1A and B for CFS 
and healthy subjects respectively. By computational 2D gel image 
comparison, 52 protein spots were found to be differentially expressed 
exhibiting ≥1,5 fold-change of mean value spot intensities in the CFS 
with respect to control samples. Only the spots that showed                 
p values < 0.01 (13 spots) were cut off and subjected to nanoLC-ESI-
MS/MS analysis for the identification. These protein spots collapsed 
into the identification of 11 different proteins.                                      
A list of identified proteins, MW, pI, score and coverage values of 
MS/MS, are shown in Table 3. The statistical analysis (mean ± SEM) 
with p-value and fold-change in expression levels between CFS and 
control is given in Table 4.  
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Figure 4: 2DE patterns of human salivary pool: CFS subjects (A) and healthy subject (B).        
A total of 200 μg of proteins was separated by 2DE using 18 cm pH 3-10L strips and 12.5% SDS-
PAGE. The 13 spots differently expressed in CFS in respect to control are indicated. 
 
A B 
3  IPG              10 3  IPG              10 
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Table 3: MS/MS data of salivary proteins found differentially expressed between pool of whole saliva of CFS patient and healthy patients – ID:                                                        
SwissProt accession number of the protein; Gene name: name of the corresponding gene; Matched peptides: the number of unique peptides on which the protein 
identification is based; Coverage: the percentage of the protein's sequence represented by the peptides identified by MS;                                                                                                                                                
Best Ion Score: it is a measure of how well the observed MS/MS spectrum matches to the stated peptid (obs.: observed; th.: theoretical). 
Spot # Protein  
name 
ID Gene  
Name 
MW 
KDa 
pI Matched 
peptides 
 
Coverage 
% 
Best ion 
score. 
    obs th obs th    
263 Serotransferrin P02787 
 
TF 
 
72 
 
77,06 
 
6,52 
 
6.81 
 
19 
 
32 
 
98,0 
 
616 Alpha Enolase P06733 ENO1 48 47,17 6,43 7,01 11 33 103,5 
1284 Zinc-alpha-2-glycoprotein P25311 AZGP1 37 
 
34,26 
 
5,35 
 
5,71 
 
9 
 
31 
 
81,5 
 
3040 Cystatin-B P04080 CSTB 15 11,4 6,63 6,96 4 70 
 
95,9 
 
806 SerpinB1 P30740 SERPINB1 
 
42 42,74 5,7 5,9 14 37 102,5 
3231 
 
Serotransferrin 
 
P02787 
 
TF 
 
76 
 
77,07 
 
6,6 
 
6,81 
 
18 
 
27 
 
97,1 
 
637 
 
Ig alpha-1 chain C region P01876 
 
IGHA1 
 
46 
 
37,65 
 
5,75 
 
6,08 
 
2 
 
8 
 
95 
 
1706 
 
Glutathione S-transferase 
P 
P09211 
 
GSTP1 
 
30 
 
23,35 
 
5,35 
 
5,43 
 
7 
 
48 
 
145,6 
 
2780 
 
Prolactin-inducible 
protein 
P12273 
 
PIP 
 
18 
 
16,57 
 
4,83 
 
8,26 
 
2 
 
16 
 
61 
 
3320 
 
Polymeric 
immunoglobulin receptor 
 
P01833 
 
PIGR 
 
67 
 
83,28 
 
5,07 
 
5,59 
 
2 
 
2 
 
35,9 
 
789 
 
Carbonic anhydrase 6 
 
P23280 
 
CA6 
 
42 
 
35,36 
 
6,34 
 
6,21 
 
3 10 70,2 
 
785 
 
SerpinB1 P30740 SERPINB1 42 
 
42,74 
 
6,64 
 
5,9 
 
8 26 110,2 
3316 
 
Alpha Enolase P06733 ENO1 41 47,17 6,63 7,01 10 26 116,3 
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Spot 
# 
Protein  
name 
p - 
Value 
 
 
Fold CFS                                  
± SD 
Healthy                                      
± SD  
263 Serotransferrin 0,0001 - 2,3 5,11E+06  ± 
1,44E+06 
2,20E+06 ± 8,16E+05 
 
616 Alpha Enolase 0,006 - 1,4 1,64E+06  ± 
3,62E+05 
2,31E+06 ± 4,24E+0 
5 
1284 Zinc-alpha-2-
glycoprotein 
0,004 - 1,5 3,68E+06 ± 9,85E+05 2,43E+06  ± 7,14E+05 
3040 Cystatin-B 0,01 1,3 2,91E+06      ± 
8,48E+05 
3,92E+06  ± 1,05E+06 
 
806 Serpin B1 0,02 
 
- 1,3 
 
1,89E+06 ± 3,33E+05 1,40E+06 ± 4,41E+05 
3231 
 
Serotransferrin 
 
3,32e-6 
 
- 2,4 
 
2,68E+06 ± 7,00E+05 
 
1,10E+06 ± 3,20E+05 
 
637 
 
Ig alpha-1 chain 
C region 
0,0027 
 
- 2,5 
 
5,91E+05 ± 3,16E+05 
 
2,36E+05 ± 5,51E+04 
 
1706 
 
Glutathione S-
transferase P 
0,01 
 
1,5 
 
1,98E+06 ± 3,56E+05 
 
2,88E+06 ± 1,08E+06 
 
2780 
 
Prolactin-
inducible 
protein 
0,0001 
 
- 3,6 
 
2,72E+06 ± 1,24E+06 
 
7,47E+05 ± 3,18E+05 
 
3320 
 
Polymeric 
immunoglobulin 
receptor 
0,003 
 
1,5 
 
7,97E+05 ± 1,88E+05 
 
1,18E+06 ± 2,65E+05 
 
789 
 
Carbonic 
anhydrase 6 
0,01 
 
1,4 
 
2,92E+06 ± 8,05E+05 
 
3,97E+06 ± 1,16E+06 
 
785 
 
SerpinB1 0,0003 
 
- 2,7 
 
1,08E+06 ± 5,34E+05 
 
4,01E+05 ± 1,65E+05 
 
3316 
 
Alpha Enolase 0,003 
 
- 2,4 
 
9,33E+05 ± 5,70E+05 
 
3,90E+05 ± 2,55E+05 
 
 
Table 4: Results of 2DE statistical analysis 
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VALIDATION OF PROTEIN EXPRESSION IN CFS 
AND CONTROL SAMPLES BY USING WESTERN 
BLOT ANALYSIS AND/OR ELISA ASSAY 
 
We used western blot analysis and/or ELISA assay to validate the 
expression changes of some of the proteins identified by 2D. We 
selected a subset of 3 candidate proteins for validation by 
immunoassays, namely we confirmed the different expression of     
Zn-Alpha2, Alpha-Enolase and Serpin-B1. Moreover, we performed a 
validation of other three proteins that we previously found 
differentially expressed in the study of twins discordant for CFS [136] 
namely Cyclophilin, Psoriasin and Cystatin-C.  
Protein validation was performed on 41 CFS and 40 control saliva 
samples. For each tested protein the optical density of specific 
immune reaction was determined and the resulting                        
mean values ± SEM were compared.  
Histograms show the volumes of the proteins found in significantly 
different quantities in WS of patients with respect to the healthy 
subjects. For the 2DE analysis the bar chart represents the mean±SD 
of optical density of  each spot. Significant differences are based on 
unpaired t test; (*p<0.05, **p<0.01, ***p<0.001). 
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PROTEINS 
 
Zn-Alpha 2 
 
According with 2DE analysis, both western blot analysis and ELISA 
assay confirmed the up-regulation of this protein in our saliva samples 
of CFS patients with respect to healthy subjects. (Graph 3).  
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Graph 3: histograms of the normalized volume (M±SD) obtained with 2DE and ELISA-Kit for 
this protein.  
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Graph 4: Western blot analysis of and the respective histograms of the optical density (OD). 
Each bar represents the mean±SD 
 
Zinc α2-glycoprotein (ZAG) is a protein of interest because of its 
ability to play many important functions in the human body, including 
fertilization and lipid mobilization. Its expression is regulated by 
glucocorticoids. Due to its high sequence homology with lipid-
mobilizing factor and high expression in cancer cachexia, it is 
considered as a novel adipokine. On the other hand, structural 
organization and fold is similar to MHC class I antigen-presenting 
molecule; hence, ZAG may have a role in the expression of the 
immune response [149]. 
In addition, ZAG is used as biomarker for identification of female 
breast and male prostatic tumors. The transcriptional regulation of 
ZAG by androgen reveals its direct role in tumor progression as 
observed for other tumor-proliferating proteins such as prostate-
specific antigen, prostatic acid phosphatase, apolipoprotein D, and 
progastriscin. The potential multiple functions of ZAG are not only a 
sensitive biomarker of tumor proliferation but it is also attributed to 
several functions such as regulation of melanin production, RNase 
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activity, and transport. Moreover, ZAG may be a potential therapeutic 
target, with its over-expression and under-expression being either 
beneficial or deleterious [149]. 
Beyond this action other study observed a role of ZAG in the 
activation of AMP kinase (AMPK), an important regulator of energy 
metabolism, in human skeletal muscle cells [150]. The mechanism 
may be involved in mediating the effects of ZAG in relation to 
increased energy utilization. This is interesting if we consider that 
several studies suggest an organic cause for CFS related to defects in 
oxidative metabolism. In particular, individuals with CFS reach 
exhaustion (in the presence of reduced sarcoplasmic ATP 
concentrations) much more rapidly in respect to healthy subjects with 
resultant acceleration of glycolysis in working skeletal muscles [151]. 
Moreover, one of the primary symptoms of CFS is muscle pain and 
weakness; this process is probably the result of cellular changes [151] 
such as reduction in the number of motor units and atrophy due to 
disuse. Considering that Russell and colleagues have demonstrated the 
ability of ZAG to reduce reactive oxygen species (ROS) production 
and to counter muscle atrophy associated with insulin resistance and 
other catabolic conditions [152]. 
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 Serpin-B1 (Leukocyte Elastase Inhibitor) 
 
Western blot analysis also confirmed the increase of expression found 
by 2DE of Serpin-B1, in CFS when compared with control samples 
(graphs below).  
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Graph 5: histograms of the normalized volume (M±SD) obtained with 2DE featuring        
Western blot analysis and the respective histograms of the optical density (OD). 
Each bar represents the mean±SD 
 
Serpin B1 also known as Leukocyte elastase inhibitor is a protein that 
in humans is encoded by the SERPINB1 gene; is a cytoplasmic serine 
protease inhibitor of polymorphonuclear neutrophils. Among other 
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serine proteases, it specifically inhibits neutrophil elastase, PR3 and 
cathepsin G, all found in neutrophil granules, by a suicide inhibition 
mechanism. 
Recent studies suggest that Serpin B1 could provide protection in the 
airways by regulating excess protease activity associated with 
inflammatory lung disorders [153]. 
Uchiyama K, in addition, founded that SerpinB1 may be a novel 
marker of active ulcerative colitis and may play an important role in 
the pathogenesis of inflammatory bowel disease [154].  
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Alpha Enolase 
 
As shown in the Table 3 two spots with different observed MW and/or 
pI are present for Alpha enolase suggesting the existence of protein 
isoforms or post-translational modifications for this protein in our 
samples. Comparative analysis suggested different level of expression  
of these spots in CFS. Western blot analysis evidenced the presence of 
two immunoreactive bands at different MW (band1=59kDa and 
band2=47kDa) as suggested by 2DE. Nonetheless, the analysis of 
optical densities of all samples suggested a significant increase of 
expression for both two bands in CFS with respect the control (see 
figures) 
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Graph 1: histograms of the normalized volume (M±SD) obtained with 2DE analysis for these 
proteins for the two spots of interests.  
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Graph 2: Western blot analysis of and the respective histograms of the optical density (OD). 
Each bar represents the mean±SD. 
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Psoriasin 
 
As far as psoriasin is concerned increase of expression was suggested 
after  comparison of twins discordant for CFS. Using Western Blot 
analysis and ELISA assay the level of expression of this protein was 
also investigated in our  cohort of CFS patients. The results obtained 
are reported below. The psoriasin up-regulation is confirmed 
significant with both the approaches. 
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Graph 6: histograms of the normalized volume (M±SD) obtained with 2DE in Twin and in our 
subjects. Each bar represents the mean±SD 
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Graph 7: Western blot analysis and the respective histograms of the optical density (OD); 
histograms of the normalized volume (M±SD) obtained with ELISA-Kit for this protein.  
Each bar represents the mean±SD 
 
Psoriasin is a relatively new member of the S100 gene family that was 
first identified as a 11.4 kDa protein induced in squamous epithelial 
cells of the epidermis isolated from skin involved by psoriasis. The 
normal function of this protein is unclear it might be deduced from its 
close relatives. The S100 proteins are believed to infuence calcium 
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mediated signal transduction and cellular events through direct target 
protein interactions, as opposed to a function as                                    
mere storage buffers [155].  
More recently, Psoriasin and the related S100 A8 and A9 proteins 
have also been found in other abnormal epithelia, including neoplastic 
breast ductal epithelium and bronchial epithelium in individuals    
with cystic fibrosis. Psoriasin might exert an epithelial migration 
inhibitory function in in-situ breast carcinoma cells that once lost 
could contribute to the onset of successful invasion [155]. 
Furthermore S100A7 is up-regulated in the saliva of patients with 
systemic sclerosis when compared to healthy individuals and has been 
proposed as a potential biomarker for systemic sclerosis with 
pulmonary involvement as demonstrated by studies conducted by 
Giusti and Baldini [156, 157]. 
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Cyclophilin 
 
Similarly to psoriasin, the increase of expression of Cyclophilin found 
in twin affected by CFS was confirmed in our cohort of patients  
Results are showed below. 
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Graph 8: histograms of the normalized volume (M±SD) obtained with 2DE and ELISA-Kit for 
this protein. Each bar represents the mean±SD 
 
 
59 
 
Cyclophilins (CyPs) are a family of ubiquitous proteins evolutionarily 
well conserved and present in all prokaryotes and eukaryotes [158]. 
They have peptidyl prolyl isomerase activity, which catalyzes the 
isomerization of peptide bonds from trans form to cis form at proline 
residues and facilitates protein folding [159].  
Human CyPs consist of 16 family members that are structurally 
distinct. Among them, the most abundant member is CyPA, which 
makes up B 0.1–0.6% of the total cytosolic proteins [158, 160] CyPA 
was initially purified from bovine thymocytes and identified as the 
primary cytosolic binding protein of the immunosuppressive drug 
cyclosporin A (CsA) [161].  
CyPA is believed to have important roles in many biological 
conditions including protein folding, trafficking,                               
and T-cell activation [162] CyPA is involved in several human 
disease. One of these is the viral infections; in this kind of disease 
have been discovered to promote the secretion of CYPA [163-165] 
supporting the hypothesis that a persistent viral infection may 
contribute to the pathogenesis of CFS [166].  
In addition, CyPA is involved in development of Rheumatoid Arthritis 
(RA). Previous study have shown that CyPA was increased in the 
synovial fluids of RA patients compared with knee osteoarthritis 
patients [167].  Influence of this protein in RA was also demonstrated 
by Won-Ha Lee which demonstrated that macrophages of the synovial 
lining layer constitute the major source of CyPA. In addition, they 
showed that stimulation of monocytes with CyPA results in increased 
production of inflammatory cytokines [168]. 
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Cystatin C  
 
In twin study Cystatin C expression, unlike Psoriasin and Cyclophilin, 
is down-regulated in CFS twin with respect the healthy.  
Validation performed in the cohort of CFS patients showed a 
discordant result as showed in the figure. In fact a significant increase 
of Cystatin C was observed in CFS patients with both western blot and 
ELISA kit approaches.   
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Graph 9: histograms of the normalized volume (M±SD) obtained with 2DE in the twin studty for 
this protein. Each bar represents the mean±SD 
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Graph 10: histograms of the normalized volume (M±SD) obtained with WB and with ELISA-Kit 
fot  this protein. Each bar represents the mean±SD 
 
Cystatin C belongs to the cystatin superfamily 2 and is a secreted 
protein, produced by most nucleated cell types; hence, it is present in 
all investigated biological fluids. Since cystatin C is a secreted protein, 
its major site of function is in the extracellular                        
compartment [169, 170]. Cystatins are Proteins with a role in protein 
catabolism, in regulation of hormone processing and bone resorption, 
in inflammation, in antigen presentation and T-cell dependent immune 
response as well as resistance to various bacterial                              
and viral infections [136].  
In relation to arthritis, cystatin C has been found to be the most 
prominent cystatin in synovial fluid of RA patients and that RA 
patients have significantly lowered levels of                               
cystatin C in circulation [171]. In addition, cystatin C has been shown 
to enhance fibroblast and smooth muscle cell proliferation and 
neutrolphil function [172-174]. 
Furthermore it was demonstrated that the two types of cystatins (type I 
and II). different functions, e.g., type I cystatins are up-regulated in 
tumor tissue while type II cystatins are generally downregulated in 
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tumors [175]. Therefore, results obtained by Ciriega could suggest 
that the balance between cysteine proteinases and their inhibitors is 
impaired in CFS [136]. 
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Conclusion 
 
Overall our results suggest the applicability of a proteomic approach 
on whole saliva to search potential biomarkers of CFS. The pilot study 
performed in a couple of omozygotic twins discordant for CFS 
suggested a list of proteins of interest as potential biomarkers. 
In this work we applied the proteomic analysis of whole saliva in a 
large cohort of patients affected by CFS and healthy subjects as 
control and we confirmed the potential role of some proteins such as 
Psoriasin, SerpinB1 and Cyclophilin as potential marker of this 
disease. 
Discordant results found for the Zn-alpha2, Cystatin-C and Alpha 
Enolase expression in our study with respect the twin study could be 
due to different clinical parameters.  
We investigated if the trend difference observed for Zn-alpha2 and 
Cystatin-C in CFS patient population were correlated with some 
clinical parameters of the patients.  
Indeed, we can definitely say, thanks to past research, that an 
important aspect that characterizes CFS patients is their psychiatric 
profile.      
A first analysis performed on our patients divided by class            
DAP (Panic Attack Disorder), EDM (Major Depressive Episode), 
BIPOLAR and DAP/BIP you may notice discordant patterns             
of the same protein in the different classes of psychiatric illness 
suggesting  a possible correlation with this profile for both proteins 
(graph 11 and 12).  
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Another important aspect is the correlation with the clinical 
parameters such FIQ, VAS (pain, fatigue, sleep) FACIT etc.  
From a first analysis it is possible to note how an opposing trend 
(reduction of the one part and the other increase) in the expression of 
Zn-Alpha2 then corresponds to values rather various parameters such 
as physical role, vitality, body pain, social activities.                     
Same for Cystatin-C about the parameters: social activities and 
physical role (table 5). 
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Graph 11: Histograms for the 3 psychiatric parameters (DAP, EDM and BIPOLAR). For every 
parameter We subdivided patients into three groups, based on the ratio of the volume of the band 
on the total average. Finally, I 2 groups, those with a ratio greater and smaller than 1, are 
compared with the average of the healthy subjects. 
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Graph 12: histograms for the 4 psychiatric parameters (DAP, DAP/BIP, EDM and BIPOLAR). 
We subdivided patients into three groups, based on the ratio of the volume of the band on the total 
average. Finally, I 2 groups, those with a ratio greater and smaller than 1, are compared with the 
average of the healthy subjects. 
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Table 5: Clinical Parameters for CFS subjects divided in two different group.  
First group contains subjects whose volumes, found via WB, are below average; in the other one, 
those whose volumes are superior.  
    Zn-Alpha 
2 mean 
<1 
Zn-Alpha 2 
mean >1 
Cyst 3     
mean <1 
Cyst 3               
mean >1 
FIQ 51,4 60,7 55,9 52,6 
VAS Pain 3,3 4,0 3,8 3,1 
VAS Fatigue 7,7 7,6 8,0 7,2 
VAS Sleep 7,2 7,6 7,7 6,8 
FACIT 29,2 32,5 31,2 29,0 
SF-36     
 Physical 
Functioning 
65,8 46,0 57,5 62,5 
 Role 
Physical 
20,0 6,0 9,4 22,5 
 Bodily Pain 42,0 69,0 42,5 51,9 
 General  
Health 
Status 
37,1 32,0 33,1 37,7 
 Vitality 28,0 18,0 24,4 27,0 
 Social 
Activities 
40,2 14,8 23,4 41,0 
 Role 
Emotional 
48,5 26,4 41,3 43,2 
  Mental 
Health 
60,9 58,4 58,5 61,6 
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Results found in this study confirm presence of possible biomarkers 
for the identification of CFS and the subsequent use of these for any 
future treatment. 
But what follows from this work is that the wide variety of psychiatric 
subjects involved in the study does not allow us to draw general 
conclusions. 
Certainly more research will be needed, with an expansion of the 
number of parties involved, both sick and healthy ones, and for both is 
required a clinical psychiatric-as complete as possible in order to 
compare the best the two types of subjects.  
Future studies can fully examine the genetic, familial, and unique 
environmental mechanisms that link these conditions, especially    
with regard to the social support network available to individuals   
with these conditions and to potential differences between              
men and women [113]. 
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